NCT lookup

Inclusion criteria:

* Male and female adults with a diagnosis of PD and who were heterozygous carriers of a GBA mutation associated with PD.
* Participants carrying known sequence variants associated with GBA-PD must had rapid eye movement (REM) sleep behavior disorder (RBD) confirmed by historically documented polysomnography or by questionnaire.
* Age greater than or equal to (\>=) 18 years to 80 years inclusive at the time of informed consent signing (FOR JAPANESE PARTICIPANTS ONLY: Age \>=20 years to 80 years, inclusive, at the time of signing the informed consent. Note: Japanese participants refers only to Japanese participants enrolled and living in Japan).
* Had symptoms of PD \>=2 years.
* Hoehn and Yahr (H and Y) stage of 2 or lower at baseline.
* Stable medication regimen of PD drugs for at least 30 days (at least 60 days for rasagiline) prior to randomization.
* The participant was willing to abstain from grapefruit containing products for 72 hours prior to administration of the first dose of GZ/SAR402671 and for the duration of the entire treatment period (Part 1 and Part 2, Periods 2 and 3).
* Signed written consent.

Exclusion criteria:

* Parkinsonism due to drug(s) or toxin(s).
* Participants carrying the LRRK2 G2019S mutation.
* Participants with Gaucher disease (GD) as defined by clinical signs and symptoms (i.e., hepatosplenomegaly, cytopenia, skeletal disease) and/or marked deficiency of GCase activity compatible with GD.
* Montreal Cognitive Assessment score less than 20.
* Participants with prior surgical history of deep brain stimulation (DBS).
* Participants with baseline brain MRI without contrast showing a structural abnormality that is a possible cause of their PD signs or symptoms.
* Hepatic insufficiency with liver function tests (LFT) greater than (\>) 2 times upper limit of normal at Screening Visit.
* The participant had a documented diagnosis, as per local regulations, of any of the following infections: hepatitis B, hepatitis C, human immunodeficiency virus 1 or 2.
* Renal insufficiency as defined by creatine \>1.5 times normal at Screening Visit.
* The participant had received strong or moderate inducers or inhibitors of CYP3A4 within 30 days or 5 half-lives prior to randomization, whichever is longer.
* The participant had, according to World Health Organization (WHO) Grading, a cortical cataract \> one-quarter the lens circumference (grade cortical catact-2 \[COR-2\]) or a posterior subcapsular cataract \>2 millimeters (grade posterior subscapsular cataract \[PSC-2\]). Participant with nuclear cataracts would not be excluded.
* The participant was currently receiving potentially cataractogenic medications, including chronic regimen (more frequently than every 2 weeks) of any dose or route of corticosteroids or any medication that could cause cataract or worsen the vision of participants with cataract (eg, glaucoma medications) according to the Prescribing Information.
* If female, pregnant (defined as positive beta-human chorionic gonadotrophin \[Beta-HCG\] blood test) or lactating or breast-feeding.
* Any medical disorders and/or clinically relevant findings that, in the opinion of the Investigator, could interfere with study-related procedures. This included condition(s) that precluded the safe performance of routine lumbar punctures, such as prohibitive spinal diseases, bleeding diasthesis, or clinically significant coagulopathy or thrombocytopenia.
* Current participation in another investigational interventional study.
* Any medications specifically used for treating memory dysfunction, such as, but not limited to cholinesterase inhibitors or memantine, within 30 days or 5 half-lives of these medications prior to randomization, whichever was longer.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

• Scottsdale, Arizona, United States
• Scottsdale, Arizona, United States
• La Jolla, California, United States
• Palo Alto, California, United States
• Sunnyvale, California, United States
• New Haven, Connecticut, United States
• Boca Raton, Florida, United States
• Chicago, Illinois, United States
• Chicago, Illinois, United States
• Boston, Massachusetts, United States
• New York, New York, United States
• New York, New York, United States
• New York, New York, United States
• Portland, Oregon, United States
• Portland, Oregon, United States
• Portland, Oregon, United States
• Philadelphia, Pennsylvania, United States
• Fairfax, Virginia, United States
• Kirkland, Washington, United States
• Innsbruck, Austria
• Vancouver, British Columbia, Canada
• Ottawa, Ontario, Canada
• Montreal, Quebec, Canada
• Paris, France
• Kiel, Germany
• Tübingen, Germany
• Larissa, Greece
• Haifa, Israel
• Petah Tikva, Israel
• Tel Aviv, Israel
• + 22 more on CT.gov